| Oct 1 |
SciSparc receives FDA approval for trial for Tourette syndrome therapy
|
| Oct 1 |
Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
|
| Sep 30 |
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
|
| Sep 28 |
Deals this week: Chesapeake, Visa, KKR, Mondelēz and more
|
| Sep 26 |
SciSparc signs LOI to sell entire ownership in MitoCareX
|
| Sep 26 |
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
|
| Sep 23 |
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
|
| Sep 18 |
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
|
| Sep 17 |
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
|
| Sep 16 |
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
|
